Long-Term Epilepsy-Associated Tumors
LEAT comprise a heterogeneous group of slow-growing low-grade cortical brain lesions of varying cells of origin, often seen in younger patients investigated for prolonged (≥2 y) drug-resistant epilepsy. 2 Gangliogliomas and dysembryoplastic neuroepithelial tumors (DNETs) are the most common of these tumors.
Neuronal and Mixed Neuronal-Glial Tumors

Gangliocytoma and ganglioglioma
These are low-grade neoplasms with neuronal differentiation (gangliocytoma) or both neuronal and glial differentiation (ganglioglioma). They are the commonest neoplasms associated with epilepsy and occur between 10 and 30 years of age. Over 80% occur in the temporal lobe, and raised intracranial pressure (ICP) may be a presenting feature.
MRI in gangliocytoma reveals a cortically based tumor consisting of solid T1-hypointense, T2-hyperintense components which enhance with gadolinium. Cyst formation is often appreciated on CT and MRI. 3 Radiological appearances of gangliogliomas are varied but classically show a cyst with a mural nodule in around 50%. Other manifestations include a solid mass with low to intermediate T1-weighted (T1W) and high T2W signal or a predominantly T1 hyperintense mass. Contrast enhancement of the solid component is variable. Mass effect or surrounding edema is rarely seen, although peripherally located gangliogliomas can cause scalloping of the overlying calvaria due to slow growth resulting in bone remodeling. These tumors frequently contain calcification.
Histologically, gangliocytomas are composed of welldifferentiated neuronal (ganglion) cells that display architectural disarray and cytological dysmorphism (Fig. 1A) , including binucleate forms. Eosinophilic granular bodies, Rosenthal fibers, and perivascular lymphocytes are common features. Gangliogliomas are similar but by definition contain an additional neoplastic glial population. Histological differential diagnoses include DNET, pilocytic astrocytoma, and diffuse gliomas. Genetic events which characterize astrocytomas are absent in ganglion cell tumors.
Gross tumor resection (GTR) is the treatment of choice, resulting in 5-year overall survival (OS) of >90%. The role of adjuvant radiotherapy is unclear. In a retrospective study of 402 patients with gangliogliomas, the 10-year local control rates were 89% after GTR, 90% after GTR plus radiotherapy, 52% after subtotal resection (STR), and 65% after STR plus radiotherapy. 4 The corresponding 10-year OS rates were 95%, 95%, 62%, and 74%, respectively (P < 0.001). Radiotherapy after STR significantly improved local control (P = 0.004) but not OS (P = 0.22) but improved neither local control nor OS after GTR.
Posterior cranial fossa gangliogliomas usually have an infiltrative brainstem component which limits resection. In children, GTR was achieved in only 58.3% of brainstem tumors compared with 68% in other sites. 5 In data from the Surveillance, Epidemiology, and End Results program, brainstem location is associated with a 5-year OS of 80.6%. 5 Surgical attempts to remove well-circumscribed enhancing components of gangliogliomas improve long-term outcome. When resection is not feasible, ventriculostomy to relieve intracranial pressure followed by observation is appropriate. Radical radiotherapy (potentially curative doses of ≥54 Gy given for inoperable or macroscopic residual disease) should be considered for symptomatic progression.
Recurrences are generally managed with further surgery. BRAF V600E mutation has been described in 20-60% of gangliogliomas and reports suggest that vemurafenib, a BRAF inhibitor, can lead to sustained clinical improvement for 6 months to 2 years. 6 
DNET
Dysembryoplastic neuroepithelial tumors are the second most common tumors in patients undergoing surgery for intractable epilepsy. Mean age of onset of seizures was 8.1 years and >90% of patients have had an episode of seizures (generally complex partial) before 20 years.
These tumors are located in the cortex and vary on imaging 7 ( Fig. 2A-E) . Type 1 tumors are strongly hypointense cystic or polycystic well-delineated lesions on T1W MRI. Type 2 tumors are nodular with mixed-signal intensity, whereas type 3 are iso-or hypointense on T1W MRI. 8 They do not show perilesional edema or mass effect.
Specific features include a wedge-shaped lesion pointing toward the ventricle, or a multicystic lesion. More recently described findings are a rim of high fluid-attenuated inversion recovery (FLAIR) signal at the lesional border and high apparent diffusion coefficient values within the lesion.
Histologically, DNETs are multinodular intracortical neoplasms. They can be divided into simple and complex variants. Both have a specific glioneuronal element with oligodendroglial-like cells in columns and patterned intracortical mucin-rich nodules with characteristic "floating neurones" (Fig. 1B) . Complex variants also show glial nodules which may be indistinguishable from pilocytic astrocytoma. Mutations of isocitrate dehydrogenase (IDH) and loss of heterozygosity 1p/19q are not seen. BRAF V600E mutations (4-51%) and activation of the pathways of mammalian target of rapamycin (mTOR) (90%) and mitogen-activated protein kinase (MAPK) (50%) have been reported.
Excision of the lesion, which controls seizures, is often sufficient. 9 Although an earlier study did not report tumor recurrence following GTR (median follow-up, 21.6 mo), 10 a recent series (n = 51) reported recurrence in 3 of 30 patients post GTR and tumor growth in 6 of 18 patients post STR at a mean follow-up of 4.5 years. 11 There are reports of malignant transformation of DNET to astrocytoma or oligodendroglioma, particularly following STR. 11 In summary, GTR followed by routine follow-up is recommended for DNET. The role of adjuvant treatment after STR is unclear. Patients with recurrence should have further surgery. 12 
Desmoplastic infantile astrocytoma/ganglioglioma (DIA/DIG)
These are supratentorial, durally based, cystic tumors occurring predominantly in male infants, generally in the first 2 years of life. 13, 14 The classical presentation is increase in head size with a bulging fontanelle, and 25% present with seizures. Children can also present with developmental delay. 13 MRI shows a mass expanding more than one lobe with a large cystic and smaller solid component attached to the meninges with dural enhancement (Fig. 2F-I ). Radiological differentials include pleomorphic xanthoastrocytoma, ganglioglioma, and primitive neuroectodermal tumor.
Microscopically, these tumors have a distinct leptomeningeal component composed of spindle cells with associated collagenous desmoplasia (Fig. 1C) . They also have a neuroepithelial component featuring small neoplastic neuronal cells and dysplastic ganglion cells (Fig. 1D ) which can be clustered or isolated within the desmoplastic region. Mutations of p53 and deletions of 1p/19q are not encountered. 15 BRAF mutations have been detected in some tumors.
Even though these tumors can be easily differentiated from brain tissue perioperatively, GTR was possible in only 54% of tumors because of extensive disease and/or tumor involving deep structures. 13, 15 The reported recurrence-free interval following GTR ranged from 6 months to 19 years. Malignant transformation to glioblastoma has been reported. 16 In summary, GTR is standard of care for DIA/DIG. The role of adjuvant radiotherapy following STR is unknown. Recurrent tumors are treated with re-excision, chemo, and BRAF inhibitors (eg, vemurafenib). Radiotherapy is generally avoided to prevent diencephalic dysfunction.
NeuroOncology
Papillary glioneuronal tumor (PGNT)
These tumors can occur in both sexes, with the median age at presentation being 23 years. 17, 18 They are usually hemispheric, mainly in the temporal lobe, but also can involve the paraventricular white matter. Clinical presentation is nonspecific, with headache and seizures common. 18 Radiologically, they are comparable to gangliogliomas, being cystic lesions with a mural nodule that may enhance with contrast and can be located close to the ventricles. 17, 19 Histologically, they are defined by the presence of pseudopapillary structures composed of a central fibrovascular core with a layer of spindled to cuboidal cells strongly immunoreactive for glial fibrillary acidic protein (GFAP). There is also typically an interpapillary population of synaptophysin-positive neurocytic cells. Molecular studies suggest that PGNTs have a dysregulation of the MAPK pathway. Fusion of solute carrier family 44 member 1 and protein kinase C alpha (SLC44A1-PRKCA), detectable by fluorescence in situ hybridization, is emerging as a specific characteristic of PGNT with a high diagnostic value.
GTR is the treatment of choice. In the largest series of 71 patients, GTR was possible in 52 (73.2%). 18 At median followup of 1.5 years (range, 0.2 to 19 y), OS and progression-free survival (PFS) were 80%. This study did not assess the effect of resection on survival. Adjuvant radiotherapy following surgery has limited evidence and therefore is not recommended.
Other Gliomas
Angiocentric glioma (AG)
These tumors mainly affect children and young adults (median age, 16 y). They are usually located in the frontal and temporal lobes but have been reported in the midbrain, hippocampus, and amygdala. 20 The most common presentation is epilepsy (up to 88%) followed by headache and visual symptoms. 20 MRI shows a well-demarcated, non-enhancing lesion, hyperintense on T2W and hypointense on T1W. There is a characteristic T1W hyperintense rim and stalk-like extension toward the ventricles.
Histologically AG demonstrates both ependymal and astrocytic characteristics (Fig. 1E) . These tumors consist of monomorphous bipolar giant cells which accumulate along vascular structures to form pseudorosettes. 
NeuroOncology
Differential diagnoses include astroblastoma, ependymoma, and papillary glioneuronal tumors. 21 Tumor cells do not harbor IDH or BRAF mutations, and the presence of either would suggest an alternative diagnosis. There is one report of malignant transformation to anaplastic ependymoma. 22 GTR is associated with better tumor control. The role of adjuvant radiotherapy after STR is unknown. In a review (n = 88), only 1 (2.7%) of the 37 patients post-GTR had seizure recurrence, whereas 44% of the 16 patients post-STR did. 20 In this series, 83 patients were followed up for a median of 24 months and only 5 had tumor recurrence (3 post-GTR, 1 STR, 1 unknown). Time to recurrence ranged from 6 months to 12 years. Adjuvant radiotherapy was used in 5 patients (3 post-GTR and 2 post-biopsy). One patient's tumor recurred post-GTR and radiotherapy within 6 months, but that tumor had high-grade histological features. Both of the patients who had radiotherapy following biopsy showed tumor regression on follow-up MRI.
In summary, GTR is the recommended treatment. After STR or biopsy, patients should have regular imaging; there is no role for routine adjuvant treatment.
Other Astrocytic Tumors
Pleomorphic xanthoastrocytoma (PXA)
PXAs are rare grade II tumors of children and young adults, with median age at presentation of 26 years. 23 The most common location is the temporal lobe and they usually present with headache and seizures.
The classic radiological manifestation is a cystic tumor that is adjacent to the peripheral leptomeninges with a strongly enhancing mural nodule (Fig. 3A-D) . PXAs are usually avascular on angiography. A reactive dural tail means it may mimic meningioma. Perilesional edema is common.
Histologically, PXAs are characterized by spindled astrocytic or mesenchymal-like areas, xanthomatous cells, eosinophilic granular bodies, and large cells with bizarre-looking, pleomorphic multinucleated cells (Fig. 1F) . Malignant transformation to a higher-grade glioma has been described.
GTR is recommended and the extent of resection correlates with OS. 23 Local recurrence can occur in 15-20% of cases, and the role of adjuvant treatment is unknown. Adjuvant radiotherapy may be offered for residual tumors with high MIB index (>5%). 24 BRAF V600E mutation is detected in 60% to 70% of tumors and is associated with better outcomes. Four patients with recurrence after resection, adjuvant radiation, and alkylating chemotherapy received 4 weeks of vemurafenib with median PFS of 5 months and median OS of 8 months. 25 Recent reports also highlight the efficacy of BRAF inhibitors in PXA. 26, 27 Non-Long-Term Epilepsy-Associated Tumors
Neuronal and Mixed Neuronal-Glial Tumors
Rosette-forming glioneuronal tumors (RGNTs)
These were originally described in the fourth ventricle but have been reported in the chiasm, suprasellar region, pineal gland, and spinal cord. 28 Commoner in females, mean age at diagnosis is 29 years. 28 The commonest presentation is headache followed by ataxia and nystagmus. Due to the long-standing nature of the tumor, hydrocephalus may be chronic.
On MRI, they appear hypointense on T1W and iso-or hyperintense on T2W images (Fig. 3F-H ) and are relatively well circumscribed, heterogeneous, and variably contrast enhancing. Pilocytic astrocytoma is a differential diagnosis. The recently described "green bell pepper sign" is based on the post-contrast appearances of RGNTs-central hypointensity surrounded by thin/no enhancement with an enhancing ring. 29 The central component is typically hypointense on diffusion-weighted imaging, which may aid in differentiation from highgrade tumors.
Histologically, there are 2 components, neural and glial (Fig. 1G) , with the latter predominating. The neural component consists of small uniform neurocytes forming Homer Wright and perivascular rosettes. The glial component often resembles pilocytic astrocytoma. GFAP is positive in the glial component, and the neurocytes express synaptophysin.
Surgery is recommended. Because of the indolent nature of this tumor, STR and relief of hydrocephalus may be sufficient. In a review of 58 cases, there were 4 recurrences; time to recurrence was 10 years in 2 cases and 9 and 4 years in another 2. 28 Regular long-term follow-up is necessary. The role of adjuvant treatment is unknown.
Other Gliomas
Chordoid glioma of the third ventricle (CG)
The age at presentation of these grade II tumors is approximately 46 years, with female predominance. 30 Only 80 cases are reported, with 3 in children. 31 They are located in the anterior third ventricle but may occur elsewhere.
Presenting symptoms include headache, nausea, visual disturbance, and limb weakness. This is due to mass effect or invasion of adjacent structures, and 25% present with hydrocephalus. 32, 33 Hypopituitarism and syndrome of inappropriate antidiuretic hormone secretion have been reported.
On MRI, a CG tumor appears as a well-defined ovoid mass in the third ventricle, hyperintense on T2 and hypointense on T1 with avid uniform contrast enhancement (Fig. 4A-D) . Occasionally there are small peripheral cystic changes.
Histologically CG tumors are composed of cords and clusters of epithelioid cells on a mucoid stroma (Fig. 1H) , often with an associated lymphoplasmacytic infiltrate. 34 High-grade features are absent. Histopathological differentials include chordoma and chordoid meningioma. Immunohistochemically, the tumor cells are positive for GFAP, vimentin, CD34, and thyroid transcription factor 1. Genetic mutations in epidermal growth factor receptor, murine double minute 2, and cyclin-dependent kinase 4 are absent, suggesting a distinct origin from other gliomas and meningiomas.
GTR is recommended but is achievable in only 44% of patients. 35 Postoperative mortality may be as high as 33%, and pulmonary embolism (42%) and infection, including meningitis, were leading causes of death. 30 Postoperative morbidities include diabetes insipidus, hypothermia, hyponatremia, hypotension, weight gain, severe shortterm memory loss, and psychosis. 20, 36 After STR, tumors enlarge slowly, although rapid growth has been reported. Adjuvant fractionated radiotherapy (54 Gy in 30 fractions) or radiosurgery (marginal dose of 12 Gy) may be considered after biopsy or incomplete resection; the exact benefit of such an approach is unknown because of small numbers. 20 
Astroblastoma
Astroblastoma typically occurs in the frontoparietal region in children and young adults (median age range, 16-35 y). 37, 38 Presenting symptoms include raised ICP, focal neurology, or seizures. Radiologically, they are large, well-defined peripheral solid tumors with multiple intratumoral cysts giving a "bubbly" appearance. They are hypointense to isointense on T1W and hyperintense on T2W and enhance heterogeneously with contrast, often as a rim. Calcification within the tumor is consistently reported, most often punctate. Peritumoral edema is described as a risk factor for early recurrence or progression.
Histologically, astroblastomas are composed of spindleshaped cells with short, broad processes arranged around vessels to form pseudorosettes (Fig. 1I) , often with vascular sclerosis. Cells stain for vimentin, S-100, GFAP, epithelial membrane antigen, cytokeratin, and oligodendrocyte transcription factor but not IDH1/2. While astroblastoma is generally considered to be low grade, higher grade is indicated by increased mitotic rate, cellular atypia, and necrosis.
GTR is recommended and feasible in 75-84 % of cases. Reported 5-year OS is 48.5% and GTR is associated with an improved 5-year PFS (83% vs 55%, P = 0.011) compared with STR. [37] [38] [39] Adjuvant radiotherapy has been used after STR but its benefit is unclear. 37, 39 Re-excision, radiotherapy, and chemotherapy are used at recurrence, and up to 30% had transformed to higher grade at salvage surgery. 37 
NeuroOncology
Choroid Plexus Tumors
Choroid plexus papilloma (CPP) and atypical choroid plexus papilloma (aCPP)
Choroid plexus tumors are rare and occur mostly in children, nearly half of them under 2 years. 40 Most CPPs are sporadic but some are associated with Li-Fraumeni syndrome. In children, the commonest site is the lateral ventricle (43%), while in adults it is the posterior fossa. 41 The majority of supratentorial CPPs present at <20 years, with features of raised ICP in infants.
CT scan shows an iso-or hyperdense mass with calcification present in 4-20%. 41, 42 On MRI, they are caulifloweror mulberry-like lesions which are iso-or hypointense on T1W. T2W images show hyperintense or mixed signal with occasional flow voids with avid contrast enhancement. 41 They are very vascular tumors with high risk of intraoperative hemorrhage. Heterogeneous enhancement, irregular contours, and parenchymal invasion may suggest choroid plexus carcinoma (CPC). Imaging of the entire neuraxis is warranted with all choroid plexus tumors to exclude disseminated disease. 42, 43 Choroid plexus tumors have been subclassified into CPP (defined as <2/10 mitoses per high-powered field [HPF], WHO grade I) (Fig. 1J) , atypical CPP (2-5 mitoses per HPF, WHO grade II), and CPC with hallmarks of malignancy such as nuclear pleomorphism, necrosis, and >5 mitoses per HPF. However, all choroid plexus tumors may disseminate throughout the neuraxis or undergo malignant transformation, and therefore are best considered as a spectrum from CPP to CPC. The biggest diagnostic challenge is to identify a truly benign CPP from an aCPP that has the potential to recur, and studies need to be done to identify suitable molecular markers.
Outcomes 45 Late recurrences (>5 y after initial treatment) are reported, so MRI surveillance is essential.
Neuronal and Mixed Neuronal-Glial Tumors
Dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos disease)
This occurs predominantly in young adults (median age, 34 y) and >200 cases have been described. 46 It is strongly associated with Cowden syndrome (a multiple hamartoma neoplasia complex associated with mutations in phosphatase and tensin homolog [PTEN] ) and so may also be a hamartoma. Most patients have a germline loss of one PTEN allele and somatic loss of the remaining allele allowing for abnormal growth. Lhermitte-Duclos disease usually presents with features of a posterior cranial fossa mass such as cranial nerve palsies and ataxia and rarely as obstructive hydrocephalus.
Imaging alone may be sufficient to make this diagnosis as the radiological findings are so specific and compelling that no realistic differential diagnosis exists. 47 The characteristic appearance on MRI is of a cerebellar mass with typical striations of alternating hypo-and hyperintense bands on T1W and T2W MRI, a "tiger-striped folial" pattern 48 ( Fig. 4E-H) . CT features are of a hypo-or iso-attenuating lesion compared with cortex, making it difficult to appreciate. Most tumors do not enhance, and mass effect causing fourth-ventricular obstruction is common.
Histologically there is disruption of the cerebellar cortex and replacement of the granular layer with large dysplastic ganglion cells (Fig. 1K) . Features of malignancy are absent. 49 Resection is the treatment of choice but may require shunt placement prior to maximal safe tumor resection. GTR may be difficult because tumor definition is difficult perioperatively, 50 but should be attempted because of the possibility of recurrence or malignant transformation. Patients thus require long-term follow-up.
Central neurocytoma (CN)
These grade II tumors represent 0.1-0.5% of primary brain tumors and arise from the septum pellucidum and the wall of the lateral ventricles. 51, 52 Median age at presentation is 34 years. Clinical presentation relates to raised ICP, most commonly papilledema and ataxia. 53 On imaging, CN appears as a well-defined, hyperdense mass attached to the lateral ventricles and close to the foramen of Monro. Lesions are iso-/hypointense on T1W MRI and hyperintense on T2W MRI. Calcification and cystic areas are common with moderate contrast enhancement. Prominent flow voids are seen on T2W imaging, and formal angiography shows a tumor blush with supply from the choroidal arteries. 54 The common differentials are ependymoma and oligodendroglioma.
Histology shows small cells with uniform round nuclei on a fine fibrillary matrix (Fig. 1L) . Definitive diagnosis requires demonstration of synaptophysin and neuronal markers on immunohistochemistry. Central neurocytomas are classified as typical (tCN) or atypical (aCN) (defined as tumors with MIB-1 index of >2%, or with atypical features such as increased mitosis, focal necrosis, and vascular proliferation).
GTR is achieved in 30-50% of patients. In an analysis of 520 cases of central neurocytomas, atypia was associated with a worse prognosis. 55 In this study, the 10-year OS and PFS were 97% and 72%, respectively, for tCN (n = 351), while the 10-year OS and PFS for aCN were 70% and 46%, respectively. For tCN, GTR (n = 137) was associated with better 10-year OS (100% vs 90%) and 10-year PFS (76% vs 43%) compared with STR (n = 90). For both tCN and aCN, adjuvant radiotherapy post GTR did not improve 5-year OS or PFS, but adjuvant radiotherapy post STR improved 5-year local control and OS for both histological subtypes. While 54 Gy is adequate for tCN, radiation dose of 55-60 Gy was associated with better 5-year local control in aCN. Adjuvant radiation is therefore recommended for atypical tumors and after incomplete resection. 56 Long-term side effects of radiotherapy, particularly in patients with typical tumors, should be weighed against the potential benefits.
Stereotactic radiosurgery (SRS) may also be an adjuvant option. 57 An analysis of 64 cases showed that adjuvant SRS results in a tumor control rate of 91% at a median of 59.3 months. 58 SRS has also been proposed as an alternative to surgery in smaller tumors without hydrocephalus. In a series of 14 patients treated to a mean tumor margin dose of 12.1 Gy there was a mean reduction in tumor volume by 69% at 65 months with neither tumor recurrence nor radiotherapy toxicity. 59, 60 In patients with recurrent disease not suitable for further surgery or radiotherapy, chemotherapy may be an option using combinations of platinum, etoposide, topotecan, and cyclophosphamide. 53 
Extraventricular neurocytoma (EVN)
This is a counterpart to central neurocytomas arising in the extraventricular parenchymal tissue and representing 0.1-0.4% of CNS tumors. 61 It is more common in the Asian population and mean age at presentation is 27 years (range, 2-75 y). Around 100 cases, including <20 in children, have been reported. 62, 63 The commonest site is the frontal lobe, but it can occur in other lobes as well as the thalamus, cerebellum, pons, and spinal cord.
Clinical presentation is usually with features of raised ICP, sometimes disproportionate to the size of the lesion. Frontal lobe tumors present with gait disturbance and behavioral/emotional changes, while temporal lobe tumors present with seizures. The average duration of onset of clinical symptoms to diagnosis was approximately 32.5 months in one series. 62 EVNs are generally well-defined lesions which are hypointense on T1W and hyperintense on T2W images, with heterogeneous contrast enhancement. There may be associated cystic degeneration, calcification, and NeuroOncology perilesional edema. They occasionally involve the cortex, which can lead to these tumors being misinterpreted as oligodendrogliomas or gangliogliomas. 64 Histological features are similar to oligodendroglioma: both have regular round nuclei but the monotonous neoplastic cells in EVN are embedded in a matrix of neuropil. EVN is less invasive and shows greater positivity for synaptophysin. Histologically they differ from central neurocytoma in higher rate of ganglion and glial differentiation. The absence of IDH mutations and 1p/19q codeletion differentiates EVN from oligodendroglioma.
GTR is treatment of choice. Approximately 27% of tumors are typical and are more common in ages >50 years as well as <18 years. Atypical tumors (having necrosis, vascular proliferation, and >3 mitoses per 10 HPF) are associated with a high risk of local recurrence and worse prognosis irrespective of extent of resection. 61 In a review of 85 cases, the median time to recurrence after initial treatment was 48 months (range, 6-216 mo) for typical tumors and 21 months (range, 5-94 mo) for atypical tumors. Rate of recurrence was 68% and mortality was 44% for atypical tumors, whereas the similar figures for typical tumors were 36% and 4%. 65 For typical tumors, both GTR and STR followed by radiotherapy were associated with reduced risk of recurrence (less than 5% and 17%, respectively). For atypical tumors, the rate of recurrence following GTR with or without radiotherapy was 33-50%, STR followed by radiotherapy was 50%, and STR alone was 100%. However, the number of patients with atypical tumors was small (n = 23) and GTR was achieved in only 13% of tumors-therefore, a definite recommendation regarding adjuvant radiotherapy is difficult.
Cerebellar liponeurocytoma
This tumor is composed of neurocytic cells with variable degrees of lipidization; >40 cases have been reported. It occurs predominantly in those aged >30 years. Most tumors occur in the cerebellum; but they can occur in supratentorial locations. Clinical presentation is with features of raised ICP or cerebellar or brainstem signs.
On imaging, these are well-circumscribed lesions located in the cerebellar hemispheres. They may be seen in the paramedian region or vermis and cause mass effect on the cerebellopontine angle. Variable signal characteristics have been described. There is often hypo/isointensity on T1W images and hyperintensity on T2W images, with heterogeneous contrast enhancement. Focal areas of T1 hyperintensity are variable and correspond to areas of high lipid content which become hypointense on fat-suppressed sequences. 66, 67 Histology shows small neurocytic cells similar to a central neurocytoma but with the addition of areas where cells resemble adipocytes. Mitotic activity is low. Necrosis and vascular proliferation are rare, but if present suggest a more aggressive course.
GTR is the treatment of choice, although in one tumor series 6 of 15 patients received adjuvant radiotherapy to a dose of 50 to 59 Gy. 68 The reported 5-year OS of 48% should be interpreted with caution given the rarity of the tumor. 69 Patients have prolonged recurrence-free intervals with surgical resection alone. In one study the average time to recurrence following resection was 10.6 years. Given the potential for late recurrence, radiotherapy has a role; but it is unclear whether it should be given immediately or delayed until recurrence. Since there are no reports of spinal metastases, adjuvant radiotherapy is given only to the posterior cranial fossa.
Other Astrocytic Tumors
Subependymal giant cell astrocytoma (SEGA)
SEGA is a tumor of >0.5 cm arising near the foramen of Monro, most common in patients with tuberous sclerosis complex (TSC). 70 It appears in the first 2 decades of life and the common presentations are features of raised ICP, focal neurology, and seizures.
Tumor location is one of the main differentiating factors for the diagnosis. It occurs when a subependymal nodule at the foramen of Monro transforms into a SEGA. On imaging, these are well-circumscribed masses with calcification and cyst formation which are iso/hypointense on T1W and iso/hyperintense on T2W images with heterogeneous contrast enhancement.
Histology shows a neoplasm composed of large cells with features intermediate between ganglion cells and astrocytes, having abundant glassy eosinophilic cytoplasm, large vesicular nuclei, and prominent nucleoli (Fig. 1M) . Conventional high-grade features are not encountered.
Surgery is indicated in symptomatic disease or with documented increase in the volume of tumor or enlargement of the ventricles. 70 Incomplete resection is associated with tumor progression. Inhibition of mTOR is the treatment of choice for patients ≥3 years with inoperable tumors. In the placebo-controlled phase III trial EXIST-1, everolimus resulted in at least 50% reduction in the tumor volume in 35% of patients treated. 71 The 5-year analysis of a previous phase II trial reported ≥50% reduction in the volume of the tumor in 52% and ≥30% reduction in volume in 61% of patients. 72 An expanded access program of everolimus (EFFECTS) reported 67.5% partial response and 29.2% stable disease with acceptable toxicity in a cohort of 120 patients. 73 The EMINENTS study showed that lowdose maintenance therapy after 12 months of standard dose everolimus is effective and leads to less frequent side effects of reduced severity. 74 While studies report reduction in size of the tumor after SRS, the response is delayed and therefore the procedure is not an option for symptomatic patients.
Mesenchymal, Nonmeningothelial Tumors
Solitary fibrous tumor (SFT)/hemangiopericytoma (HPC)
These are dural-based tumors, but SFT can rarely arise in the lateral ventricles and spinal cord. In the 2016 classification, SFT and HPC, which have overlapping pathological characteristics, including "patternless" sheets of uniform spindle cells, collagen fibers, and prominent, thin-walled ectatic blood vessels, are grouped together as these tumors exhibit a unique fusion of NAB2 (nerve growth factor-inducible protein A binding protein 2) and STAT6 (signal transducer and activator of transcription 6). The age at diagnosis is the mid30s and males are more frequently affected. These tumors can be of grades I-III. Grade I tumors were previously 75 Grade I tumors are well-circumscribed extra-axial masses arising from the dura with similar appearances to meningioma. They are typically isodense to hyperdense, may have calcifications, and can erode adjacent bone. These tumors are T1 isointense and T2 hypointense with heterogeneous enhancement. Grade II tumors are mixed iso-hypointense or isointense on T1W and mixed isohyperintense or isointense on T2W. The tumors may be uniform or heterogeneously enhancing with areas of necrosis and cystic changes, and the "dural tail" sign may be seen.
GTR is the treatment of choice and 14% of grade I tumors recur. Grades II-III tumors have a higher rate of recurrence, and case series suggest that adjuvant radiotherapy may improve PFS but not OS. Grade II tumors have a higher risk of recurrence even after GTR (>80%) and therefore, adjuvant radiotherapy is advised in tumors with malignant features and after STR. 76 
Hemangioblastoma
Hemangioblastomas account for 2% of intracranial tumors and is associated with von Hippel-Lindau syndrome. 77 It commonly occurs in patients aged 20-40 years. The commonest site is the posterior fossa, particularly the cerebellum. Presentations are with cerebellar symptoms or features of hydrocephalus. Histologically, they are composed of large vacuolated stromal cells with degenerate nuclear atypia and a rich capillary network. On imaging, these are well-defined tumors consisting of a cyst with non-enhancing walls, except for an enhancing mural nodule. The solid component, which abuts the pia mater, is T1 hypo-or isointense, T2 hyperintense.
GTR is the standard of care, and the reported local recurrence rate is 3-10%. Patients need long-term follow-up. 77 Table 1 summarizes the features and management of uncommon low-grade tumors. Primary surgery followed by close follow-up remains the standard of care. The role of adjuvant treatment is unclear. However, adjuvant treatment may be considered after STR for tumors with a significant risk of recurrence and where further surgery risks morbidity. Chemotherapy regimens are similar to those for other low-grade gliomas. Some of these tumors exhibit BRAF V600E mutation and there are reports of clinical benefit with BRAF inhibitors. 78 Importantly, all these tumors should have a structured molecular evaluation as proposed by Jones et al in 2018 to identify potentially targetable genetic alterations. 79 
Conclusion
Search Strategy and Selection Criteria
An initial search of PubMed used the broad search terms "brain tumors, " "low-grade, " "radiotherapy, " "chemotherapy, " "surgery, " and "treatment" from January 1990 to March 2018. A subsequent focused search was undertaken using the names of individual histological subtypes of low-grade brain tumors as in the 2016 WHO classification. Only papers published in English were reviewed. The final reference list was generated on the basis of originality and relevance to the broad scope of this review.
